A Ten-Year Trend of Antimicrobial Resistance in Pseudomonas aeruginosa From United States Medical Centers: Results From the INFORM Surveillance Program (2015-2024).

Helio S Sader, Rodrigo E Mendes, John Lock, Krisztina M Papp-Wallace, Mariana Castanheira

原始摘要（英文原文）· Original abstract

We evaluated 14 304 Pseudomonas aeruginosa isolates from 56 US medical centers (2015-2024). Ceftazidime-avibactam, ceftolozane-tazobactam, and imipenem-relebactam were active against 97.0%-97.9% of isolates overall. Piperacillin-tazobactam and ceftazidime activities decreased slightly during the study period, whereas the activities of meropenem, levofloxacin, and tobramycin improved since 2017.

读原文 · Read the paper ↗

AI 追问PRO

登录后使用 AI 追问

讨论区

登录后参与讨论

相关论文 · Related

Activity of Aztreonam-avibactam and Ceftazidime-Avibactam against Enterobacterales and Pseudomonas aeruginosa causing infections in patients hospitalized in hematology, oncology, and transplant units from United States medical centres (2019-2024).
Multidrug-resistant Enterobacterales in United States hospitals: Frequency and susceptibility to newer β-lactamase inhibitor combinations (2020–2024)
Antimicrobial activity of aztreonam/avibactam and molecular characterization of Enterobacterales not susceptible to ceftazidime/avibactam and/or meropenem/vaborbactam from US medical centres (2016-2024).
Current and future options for the treatment of serious infections due to carbapenem-resistant <i>Pseudomonas aeruginosa</i>
Effectiveness of imipenem-relebactam for multidrug-resistant <i>Pseudomonas aeruginosa</i> in pneumonia and bloodstream infections in the United States (MIRAGE)